This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Promethazine Hydrochloride

Read time: 1 mins
Marketing start date: 18 Nov 2024

Summary of product characteristics


Effective Time

20221031

Version

5

Spl Product Data Elements

Promethazine Hydrochloride Promethazine Hydrochloride PROMETHAZINE HYDROCHLORIDE PROMETHAZINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE HYDROXYPROPYL CELLULOSE, UNSPECIFIED HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED WHITE TO OFF-WHITE ROUND ZC;01 Promethazine Hydrochloride Promethazine Hydrochloride PROMETHAZINE HYDROCHLORIDE PROMETHAZINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED WHITE TO OFF-WHITE ROUND Z;C;0;2 Promethazine Hydrochloride Promethazine Hydrochloride PROMETHAZINE HYDROCHLORIDE PROMETHAZINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED WHITE TO OFF-WHITE ROUND ZC03

Application Number

ANDA040596

Brand Name

Promethazine Hydrochloride

Generic Name

Promethazine Hydrochloride

Product Ndc

65841-041

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 65841-040-01 in bottle of 100 tablets Promethazine Hydrochloride Tablets USP, 12.5 mg R x only 100 tablets NDC 65841-041-01 in bottle of 100 tablets Promethazine Hydrochloride Tablets USP, 25 mg R x only 100 tablets NDC 65841-042-01 in bottle of 100 tablets Promethazine Hydrochloride Tablets USP, 50 mg R x only 100 tablets Promethzine Tablets, 12.5 mg Promethazine Tablets, 25 mg Promethazine Tablets, 50 mg

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.